Jason K. Hou
Elite in Viral Gastroenteritis

Dr. Jason K. Hou

Gastroenterology
7200 Cambridge St, Ste 8B-1, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Viral Gastroenteritis
7200 Cambridge St, Ste 8B-1, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Hou, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Jason Hou specializes in Gastroenterology and works at BCM Gastroenterology. To make an appointment, please call (713) 798-0950. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted.

Dr. Hou is rated as an Elite provider by MediFind in the treatment of Viral Gastroenteritis. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 78 articles and participated in 9 clinical trials in the study of Viral Gastroenteritis.

Graduate Institution
Northwestern University Feinberg School Of Medicine
Specialties
Gastroenterology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor St. Luke's Medical Center - Houston, TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Baylor College of Medicine - Gastroenterology
7200 Cambridge St, Ste 8B-1, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Enrollment Status: Recruiting
Publish Date: November 05, 2025
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

103 Total Publications

Pharmacologic activation of HNF4α/γ Restores Epithelial Barrier Function in Crohn's disease.
Pharmacologic activation of HNF4α/γ Restores Epithelial Barrier Function in Crohn's disease.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Similar Doctors
Bincy Abraham
Elite in Viral Gastroenteritis
Dr. Bincy Abraham
Gastroenterology
Elite in Viral Gastroenteritis
Dr. Bincy Abraham
Gastroenterology

Tmh Physician Associates PLLC

7575 San Felipe St, Suite 155, 
Houston, TX 
 (7.3 miles away)
713-266-9955
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bincy Abraham is a Gastroenterologist in Houston, Texas. Dr. Abraham is rated as a Distinguished provider by MediFind in the treatment of Viral Gastroenteritis. Her top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Colitis, Endoscopy, and Colonoscopy.

Elite in Viral Gastroenteritis
Dr. Richard Kellermayer
Pediatric Gastroenterology | Gastroenterology
Elite in Viral Gastroenteritis
Dr. Richard Kellermayer
Pediatric Gastroenterology | Gastroenterology
6701 Fannin St, 
Houston, TX 
 (0.7 miles away)
832-824-7243
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Richard Kellermayer is a Pediatric Gastroenterologist and a Gastroenterologist in Houston, Texas. Dr. Kellermayer is rated as a Distinguished provider by MediFind in the treatment of Viral Gastroenteritis. His top areas of expertise are Viral Gastroenteritis, Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy. Dr. Kellermayer is currently accepting new patients.

Distinguished in Viral Gastroenteritis
Dr. Peter Lang
Gastroenterology
Distinguished in Viral Gastroenteritis
Dr. Peter Lang
Gastroenterology

Hillcroft Medical Clinic Assoc

1429 Hwy 6, 
Sugar Land, TX 
 (15.7 miles away)
713-781-4600
Languages Spoken:
English
See accepted insurances

Peter Lang is a Gastroenterologist in Sugar Land, Texas. Dr. Lang is rated as a Distinguished provider by MediFind in the treatment of Viral Gastroenteritis. His top areas of expertise are Colitis, Jaundice, Gastroesophageal Reflux Disease (GERD), Colonoscopy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hou's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile